The US FDA-approved anti-inflammatory drug cromolyn sodium has been demonstrated to delay disease progression in an ALS mouse model.
A preclinical study in mice has revealed that a specific miRNA could target and modulate the gut microbiome with precision, holding potential as a new treatment option for multiple sclerosis.
A new study has revealed that specific patterns in brain activity can indicate whether a young mouse will develop Alzheimer’s-like memory deficits in old age.
Using fluorescent tags, a team of researchers discovered a novel mechanism for synaptic plasticity that may have pharmacological applications in the treatment of epilepsy.
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
A study of more than 1000 elderly patients has revealed that there are no links between statin medication and cognitive decline.
Researchers have identified a new fear pathway between the auditory cortex and the lateral amygdala in mice that may aid further research into fear-related conditions such as anxiety and post-traumatic stress disorder.
A research team have discovered a new mechanism by which elovanoids may protect retinal and brain cells against neurodegenerative diseases such as Alzheimer’s and age-related macular degeneration.
NHS England have approved the use of cannabis-based medicines for the first time. Epidyolex can now be prescribed to children with severe epilepsy syndromes and Sativex can be prescribed to individuals with multiple sclerosis.
Chinese pharmaceutical firm, Shanghai Green Valley Pharmaceuticals, has gained conditional approval from the country’s regulatory agency for oligomannate as a treatment for mild-to-moderate Alzheimer’s disease.